Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Sitagliptin on Quality of Life in Type 2 Diabetes
NCT05167513Phase 4Completed
- Sponsor
- Getz Pharma
- Start
- Jan 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Getz Pharma. Primary endpoint: Diabetes Quality of Life assessment using DQOL-13 questionnaire at 6 months. Started Jan 2021; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05167513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167513.